TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01317628

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tobacco smoke reduction trial intervention program
Description: Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
Study: NCT04447131

Intervention type: OTHER
Intervention: venipuncture in peripheral vein
Description: single vacuum venipuncture in peripheral vein

Intervention type: OTHER
Intervention: venipuncture in peripheral vein
Description: single vacuum venipuncture in peripheral vein

Intervention type: OTHER
Intervention: venipuncture in peripheral vein
Description: single vacuum venipuncture in peripheral vein
Study: NCT01809353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54452840
Description: Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching intravenous dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching intravenous dose
Study: NCT06342687

Intervention type: PROCEDURE
Intervention: High compliance with ERAS protocol
Description: Patients were categorized into two groups based on their adherence to the ERAS protocol: group 1 with a compliance rate below 80% and group 2 with a compliance rate of 80% or above.
Study: NCT02582229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
Study: NCT01264510

Intervention type: OTHER
Group type: OTHER
Intervention: audiological test battery
Description: routine audiological measurements.
Study: NCT02621866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraviolet A radiation
Description: Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham irradiation
Description: As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of \<500nm, but permits visible light to pass.
Study: NCT02009189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Taurolidine Lock
Description: Catheter lock with 2% Taurolidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Taurolidine Lock
Description: Catheter lock with 2% Taurolidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2% Taurolidine Lock
Description: Catheter lock with 2% Taurolidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.35% Taurolidine
Description: Catheter lock with 1.35% Taurolidine + citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.35% Taurolidine
Description: Catheter lock with 1.35% Taurolidine + citrate
Study: NCT01266213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole plus Goserelin
Description: Anastrozole 1 mg p.o. plus Goserelin s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole plus Goserelin
Description: Anastrozole 1 mg p.o. plus Goserelin s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole plus Goserelin
Description: Anastrozole 1 mg p.o. plus Goserelin s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin s.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin s.c.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin s.c.
Study: NCT02355327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laselle Kegel Exerciser
Description: Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercises
Description: Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
Study: NCT01889680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: 400 mg/m2 IV day 1 every 14 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: 400 mg/m2 IV day 1 every 14 days until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: 4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: 5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: 5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
Study: NCT04709666

Intervention type: PROCEDURE
Intervention: Endsocopic Retrograde ColangioPancreatography (ERCP)
Study: NCT02148172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Plyometric Training
Description: Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plyometric Training with BWS
Description: Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
Study: NCT04300972

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body/weight adaption
Description: contrast media dose is adapted to weight and body type

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard dose
Description: a fixed amount of contrast media is used, independently of weight and body type
Study: NCT02679911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loceryl NL
Description: Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox NL
Description: Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
Study: NCT01637194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study: NCT01591187

Intervention type: OTHER
Intervention: Text messaging
Description: Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.

Intervention type: OTHER
Intervention: Questionnaire
Description: Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.

Intervention type: OTHER
Intervention: Interviews
Description: Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
Study: NCT03648957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity tracker
Description: Participants are encouraged to wear a activity tracker to monitor their physical activity
Study: NCT04653194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Combination single tablet anti-retroviral therapy: bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symtuza
Description: Combination single tablet anti-retroviral therapy: darunavir 800mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg
Study: NCT04162522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
Study: NCT00007358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone or other corticosteroid
Description: Administered during the third trimester of pregnancy
Study: NCT01031979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yohimbine
Description: alpha-2 adrenergic receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03592368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBT
Description: Interpretation bias training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IBT
Description: Interpretation bias training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IBT
Description: Interpretation bias training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IBT
Description: Interpretation bias training
Study: NCT03683342

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ankle Block
Description: Ankle block will be performed prior to surgery under ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic nerve block
Description: Sciatic nerve block will be performed prior to surgery under ultrasound guidance
Study: NCT01033916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LIBERAL
Description: The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
Study: NCT01073202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: 13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: identical-appearing placebo
Description: 13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
Study: NCT04712708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound Therapy
Description: Rebound therapy is the therapeutic use of full sized trampoline or mini sized trampoline. It provides opportunities for exercise recreation and therapy; and it is distinct from gymnastic trampolining. It is used for facilitating movements, improving balance, enhancing coordination and promoting motor performances in children with different disorders includes learning disabilities, communication disorders and motor dysfunction (Rebound Therapy South Africa, 2020; The Chartered society of Physiotherapists, 2016).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Program
Description: The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Program
Description: The Mat Exercises:~Stretching exercises to all spastic muscle groups (Kalkman et al., 2018). Gentle exercises was applied for 40-60 seconds and repeated from 3-5 times/ movement as supported by (Fragala et al., 2003).~Strengthening Exercises:~Dynamic Rising Positioning~The Gym Exercises:
Study: NCT03157284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice Flour
Description: For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
Study: NCT03080948

Intervention type: BEHAVIORAL
Intervention: survey
Description: Research assessments as part of this protocol will be scheduled during routine clinic visits

Intervention type: BEHAVIORAL
Intervention: survey
Description: Research assessments as part of this protocol will be scheduled during routine clinic visits

Intervention type: OTHER
Intervention: Saliva samples
Description: Germline DNA analysis

Intervention type: OTHER
Intervention: Saliva samples
Description: Germline DNA analysis
Study: NCT01637194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02009189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1.35% Taurolidine
Description: Catheter lock with 1.35% Taurolidine + citrate
Study: NCT03443349

Intervention type: DEVICE
Group type: OTHER
Intervention: Vibwife One
Description: Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control.
Study: NCT01637194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01200446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: 8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Docosahexaenoic Acid
Description: 8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
Study: NCT00326664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given orally
Study: NCT01455896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650

Intervention type: OTHER
Group type: OTHER
Intervention: ITCA placebo
Description: ITCA placebo
Study: NCT01831232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium
Description: Given PO
Study: NCT01706588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
Study: NCT01831232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01621139

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
Study: NCT04052711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101
Study: NCT02024997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study: NCT03451630

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Touch
Description: Intensive, in-person and/or telephonic support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-Tech
Description: Remote care management and self-directed digital tools.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimal Discharge Planning
Description: Transition to other Health Plan disease management programs and/or community resources.
Study: NCT02488564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: 50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
Study: NCT03759756

Intervention type: OTHER
Intervention: AI presentation
Description: AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.

Intervention type: OTHER
Intervention: no AI presentation
Description: AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
Study: NCT00816868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib in combination with capecitabine
Description: Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
Study: NCT02488564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
Study: NCT03703635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracranial balloon angioplasty
Description: A balloon (recommending the Neuro RX and Neuro LPS Intracranial Balloon Dilation Catheter \[Sinomed Inc., Tianjin, China\]) is navigated by the microwire to the lesion of the target artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aggressive medical management
Description: Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aggressive medical management
Description: Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/80-90 mmHg and LDL lower than 70 mg/dl or 1.8mmol/L.